Institutional members access full text with Ovid®

Share this article on:

Mitomycin C Does Not Inhibit Exacerbation of Granular Corneal Dystrophy Type II Induced by Refractive Surface Ablation

Ha, Byoung Jin MD*; Kim, Tae-im MD†‡; Choi, Seung-il PhD†‡; Stulting, R Doyle MD, PhD§; Lee, Dong Ho MD¶ ; Cho, Hyun-Soo PhD‖; Kim, Eung Kweon MD, PhD†‡

doi: 10.1097/ICO.0b013e3181c3258a
Clinical Science

Purpose: To evaluate the effect of mitomycin C (MMC) on the exacerbation of corneal opacity that occurs in patients with granular corneal dystrophy type II (GCD II) after refractive corneal surface ablation.

Methods: Ten eyes of patients with GCD II who underwent refractive corneal surface ablation with MMC were compared with 10 eyes that were not treated with MMC. Best spectacle-corrected visual acuity, the degree of corneal opacity, and contrast sensitivity were evaluated at least 3 years after surgery. Corneal opacities were quantified using Pentacam densitometry maps.

Results: No measured between-group value showed a statistically significant difference.

Conclusion: Simultaneous application of MMC does not prevent exacerbation of GCD II after refractive corneal surface ablation.

From the *Siloam Eye Hospital, Seoul, Korea; †Corneal Dystrophy Research Institute and ‡Department of Ophthalmology, Yonsei University College of Medicine, Seoul, Korea; §Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA; ¶Yonsei Eye Center, Seoul, Korea; and ‖Department of Biology, College of Life Science and Biotechnology, Yonsei University, Seoul, Korea.

Received for publication March 24, 2009; revision received July 27, 2009; accepted September 23, 2009.

Supported by a grant of the Korea Healthcare technology R&D Project, Ministry for Health, Welfare and Family Affairs, Republic of Korea (A080320).

Reprints: Eung Kweon Kim, MD, PhD, Department of Ophthalmology, Yonsei University College of Medicine, Seodaemungu Sinchondong 134, Seoul 120-752, Korea (e-mail: eungkkim@yuhs.ac).

© 2010 Lippincott Williams & Wilkins, Inc.